EcoDrugPlus

Hypocretin Receptor 2

Ensembl ID : ENSAOCG00000003881
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSAOCG00000019505
Gene Symbol: LOC111571635
3 Cross references
212 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSAOCG00000003169
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSAOCG00000009335
Gene Symbol: LOC111578142
4 Cross references
258 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b-Like

Ensembl ID : ENSAOCG00000008042
Gene Symbol: LOC111564887
4 Cross references
259 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 2

Ensembl ID : ENSAOCG00000009088
Gene Symbol: LOC111581159
4 Cross references
202 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSAOCG00000003888
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSAOCG00000023289
Gene Symbol: INSR
3 Cross references
230 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSAOCG00000023485
Gene Symbol: LOC111569056
3 Cross references
201 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSAOCG00000014811
Gene Symbol: LOC111587416
3 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSAOCG00000000439
Gene Symbol: LOC111571920
3 Cross references
206 Possible Orthologues:

Integrin Alpha-5-Like

Ensembl ID : ENSAOCG00000021629
Gene Symbol: LOC111581516
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).